ZappRx and Bayer Partner to Improve Access to Specialty Medications
ZappRx, a digital health company that streamlines the complex processes associated with prescribing specialty medications, announced an agreement with Bayer to provide a more efficient approach to the accessing of specialty medications and associated support programs.
ZappRx will support patients living with two specific types of Pulmonary Hypertension (PH) and patients with Relapsing Remitting Multiple Sclerosis (RRMS), conditions within Bayer’s Specialty Medicines portfolio. Subsequent to the integration with ZappRx’s platform, Bayer will also gain access to unique data assets and meaningful insights around the treatment of these patient populations.
“By collaborating with a global pharmaceutical company such as Bayer, we continue to build momentum around our primary goal – helping patients,” said Zoë Barry, CEO and Founder of ZappRx. “Like ZappRx, Bayer puts the patient at the center of their world and by working together we believe the impact of both organizations can be greatly amplified. This agreement constitutes another meaningful step toward transforming how specialty medications are prescribed and accessed.”
Specialty prescribing and prior authorizations are traditionally manual, paper-based processes heavily dependent on fax machines. ZappRx provides physicians with a comprehensive digital solution for specialty prescribing and prior authorization. Providers using the ZappRx platform can improve their prescription approval rate from weeks to just a matter of days, even when dealing with the most complex cases.
To learn more about ZappRx and its revolutionary application for specialty prescribing and prior authorization, please visit them at www.zapprx.com.
To learn more about Bayer, please visit them at www.bayer.us.
ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls. The platform is currently live in Pulmonary [including Cystic Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Idiopathic Pulmonary Fibrosis (IPF)], Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn’s Disease and Ulcerative Colitis). As the company grows, ZappRx plans to expand into other areas, including Rheumatology, Neurology, Oncology, and other rare diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005016/en/